Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $157.73M | $132.62M | $147.29M | $131.10M | $208.02M | $51.27M | $66.39M | $37.72M |
| Selling, general and administrative | $62.76M | $62.59M | $77.63M | $103.12M | $360.42M | $15.59M | $14.23M | $20.65M |
| Operating expenses | $220.50M | $195.21M | $224.93M | $234.21M | $568.44M | $66.85M | $65.61M | $58.38M |
| Operating income | −$220.50M | −$195.21M | −$224.93M | −$234.21M | −$568.44M | −$66.85M | −$65.61M | −$58.38M |
| EBITDA | −$220.45M | −$195.17M | −$224.88M | −$234.17M | −$568.40M | −$66.83M | −$80.60M | −$58.36M |
| Interest expense | $0 | $0 | $0 | — | $0 | $0 | −$9.00K | −$2.45M |
| Income before taxes | −$215.67M | −$189.42M | −$219.17M | −$231.79M | −$565.90M | −$62.91M | −$61.20M | −$56.25M |
| Net income | −$215.67M | −$189.42M | −$219.17M | −$231.79M | −$565.90M | −$62.91M | −$61.20M | −$56.25M |
| EPS, basic | −$0.28 | −$0.24 | −$0.29 | −$0.31 | −$0.76 | −$0.09 | −$0.08 | −$0.08 |
| EPS, diluted | −$0.28 | −$0.24 | −$0.29 | −$0.31 | −$0.76 | −$0.09 | −$0.08 | −$0.08 |
| Diluted shares | 778.18M | 775.46M | 766.70M | 743.42M | 742.62M | 738.08M | 737.82M | 726.66M |
Figures describe Summit Therapeutics shares, not any token. As of Jul 23, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.